Paper
8 January 2024 CAR-T cell therapy use in the treatment of ovarian cancer
Yican Zheng
Author Affiliations +
Proceedings Volume 12924, Third International Conference on Biological Engineering and Medical Science (ICBioMed2023); 129241T (2024) https://doi.org/10.1117/12.3013067
Event: 3rd International Conference on Biological Engineering and Medical Science (ICBioMed2023), 2023, ONLINE, United Kingdom
Abstract
The newly developed CAR-T cell therapy has got huge breakthrough in hematological malignancies. However, this method still need to be improved in the treatment of solid tumors. Ovarian cancer is one of the gynecological cancers in clinical practice, and most patients are diagnosed in the late stage, and until now there is no targeted method to cure it. Therefore, it is important to apply the therapy that discussed in the treatment of OC to decrease the death rate. However, this therapy has certain limitations and its clinical application is not positive. Thus, the scientists combine the therapies with other therapies like PD-1 and PD-Ll axis or the immune checkpoint inhibitors. Finding appropriate targets like TAG-72 and CD47 is another approach to improve the therapy. Moreover, currently there are some limitations to strict the wide spread of the therapy, for instance, the high toxicity, the low infiltration and the lack of experimental data.
(2024) Published by SPIE. Downloading of the abstract is permitted for personal use only.
Yican Zheng "CAR-T cell therapy use in the treatment of ovarian cancer", Proc. SPIE 12924, Third International Conference on Biological Engineering and Medical Science (ICBioMed2023), 129241T (8 January 2024); https://doi.org/10.1117/12.3013067
Advertisement
Advertisement
RIGHTS & PERMISSIONS
Get copyright permission  Get copyright permission on Copyright Marketplace
KEYWORDS
Tumors

Ovarian cancer

Cancer

Solids

Toxicity

Clinical trials

Antibodies

Back to Top